Global Specialty Injectable Generics Market, by Product Type (Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 31,300 million in 2017, and is estimated to exhibit a CAGR of 10.4 % over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.

Increasing research and development by market players is expected to augment the market growth.

Major market players are focusing on research and development to develop novel products and enhance their product portfolio. For instance, Oncobiologics collaborated with Ligand Pharmaceuticals to initiate a phase III trial for ONS-1045 monoclonal antibody for the treatment of colorectal cancer and lung cancer, in February 2018.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1877.

Moreover, increasing prevalence of cancer, rheumatoid arthritis, and other chronic diseases are expected to boost the market growth. For instance, according to the Rheumatoid Arthritis Support Network, around 1.3 million people in the U.S. and around 1% the world population is diagnosed with rheumatoid arthritis, in October 2018.

Browse 34 Market Data Tables and 36 Figures spread through 238 Pages and in-depth TOC on ‘Specialty Injectable Generics Market’- Global Forecast to 2026, by Product Type (Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Browse Press Release: https://www.coherentmarketinsights.com/market-insight/specialty-injectable-generics-market-1877.

Major players in the market are focusing on adopting strategies such as mergers and acquisitions to expend their product portfolio and strengthen their market position. For instance, in 2016, Teva Pharmaceutical Industries Ltd. acquired Allergan’s generics business under the name Actavis Generics. This strategic acquisition strengthened Teva Pharmaceutical Industries’ product portfolio and expand its research & development capabilities.

Key Takeaways of the Specialty Injectable Generics Market:

• The global specialty injectable generics market is expected to exhibit a CAGR of 10.4% over the forecast period, attributed to increasing prevalence of cancer, rheumatoid arthritis, central nervous system (CNS)-associated disorders, and other diseases. For instance, according to the Alzheimer Association Report 2017, around 13.8 million people were diagnosed with Alzheimer’s dementia in the U.S.

• Among product type, biologics segment held a dominant position in the specialty injectable generics market in 2018. This is attributed to increasing investments in this segment and increasing number of market players focusing on developing biosimilar version of the branded biologics injectable.

• Among application type, oncology segment held a dominant position in the specialty injectable generics market in 2018. This is attributed to increasing research and development in oncology.

• Among distribution channel, hospital pharmacies segment held a dominant position in the specialty injectable generics market in 2018, attributed to increasing number of cases related to cancer, cardiovascular diseases, and other diseases registered in hospitals

• Major players operating in the global specialty injectable generics market include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, and Dr. Reddy's Laboratories

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1877

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737